BillionToOne to Present at the 43rd Annual J.P. Morgan Healthcare ConferenceAs the villagers bid farewell to the enigmatic visitor, one question lingers in their minds: Will the Four-Legged Stranger return one day, or will it fade into legend, a fleeting memory of a captivating encounter that defied explanation?
Filamon Limited, an Australian biotech company focused on developing next-gen anti-inflammatory drugs, has announced its breakthrough dementia treatment. ALPHA-003 is designed to preserve the integrity of vital brain cell structures and protect them against destruction caused by brain inflammation. In healthy neurons, the tau protein stabilizes , crucial tube-like structures that, together with neurofilaments, maintain the neurons’ shape and provide mechanical support. However, when it’s modified, tau can form – tangles that degrade these key structures. This is seen in a group of diseases called tauopathies, such as dementia, including Alzheimer’s disease, and (CTE). Existing dementia treatments focus on reducing the consequences of this structural damage but have enjoyed only moderate success. Now, an Australian biotech company, Filamon Limited, has announced its breakthrough treatment, , which is aimed at halting the progression of dementia by preventing microtubular destruction. “The underlying problem with most forms of dementia is the destruction of a key structural component of brain cells known as microtubules,” said Associate Professor Kieran Scott, Professor of Oncology at Western Sydney University, and co-founder of Filamon. “These long, hollow tubes are vital to healthy brain function. In dementia, these microtubules degrade, resulting in the death of brain cells. “To date, no one has found a way of preventing microtubular destruction,” Scott said. “We believe ALPHA-003 has the potential to be that first drug by stabilizing the two main brain cell components whose job is to protect microtubules from damage – tau and neurofilaments.” ALPHA-003 is designed to prevent damaging brain inflammation by binding to tau and neurofilaments, providing the microtubular protection that Scott is referring to. The result of deep-learning, computational drug design technology developed in Australia, ALPHA-003 started life as a more general anti-inflammatory drug, countering the effects of human group IIA secretory phospholipase A (hGIIA), a significant player in inflammatory conditions, before its developers realized its potential for treating neuroinflammation, specifically. “ALPHA-003 was under development as a new form of anti-inflammatory drug that worked by blocking the activating effects of the key inflammatory ligand, hGIIA, on a range of cell structural proteins,” Professor Graham Kelly, Filamon’s co-founder, CEO, and Managing Director said in an interview with . “Activation of those proteins underlies most chronic inflammatory changes. Recent published data has shown that tau is another structural protein that responds to hGIIA, so we simply asked the question whether ALPHA-003 would have the same protective effect on tau. Our studies showed that it does, to the extent of blocking the ability of tau to form sheets of oligomers that comprise the ‘tau neurofibrillary tangles.’” But it wasn’t just the need to fill a treatment niche that drove the drug’s development. Kelly explained to that experiencing the devastating effects of dementia first-hand was also a motivating factor. “The personal angle has been the confronting experience of seeing a very good friend who has always been a bundle of energy and force of nature deteriorate into a tragic, sunken, shell of a woman who has lost all recognition of friends and family,” he said. But does ALPHA-003 work? Pre-clinical studies strongly suggest that it does. Importantly, the drug has been found to cross the blood-brain barrier in mammals, meaning it can exert a direct effect on brain cells. The team at Filamon were so happy with the results that they announced them prior to journal publication. “The announced news is literally freshly generated,” Kelly told . “We considered it to be of such importance to warrant being released pre-publication. More studies are underway, and the results of those studies will be the subject of journal submissions.” Kelly foresees ALPHA-003 being used to treat dementia at the time of diagnosis. “We see dementia as a two-step process involving (i) creation of an ongoing neuroinflammatory trigger, and (ii) the consequences of that trigger,” he told . “ALPHA-003 is aiming at blocking the latter, but that requires accepting that the underlying neuroinflammation trigger continues unabated. ALPHA-003 simply is aiming to mitigate the effects of the trigger. Another Filamon experimental drug program underway with another drug technology aims to deactivate this trigger.” Filamon aims to have ALPHA-003 available for use in 2026. It’s expected that the drug will treat tauopathies other than the two major forms of dementia – Alzheimer’s disease and frontotemporal dementia – such as progressive supranuclear palsy, an uncommon Parkinson’s-like disorder, and CTE, caused by repeated concussions. Source: [PDF]Alex's story serves as a powerful reminder of the strength of community and the impact that small acts of kindness and solidarity can have on those in need. It showcases the beauty of human empathy and compassion, demonstrating that when we come together to support one another, we can create a more caring and inclusive society for all.
So, as the dust settles and the echoes of victory fade away, one thing remains certain: Kyrie Irving is the Dallas Mavericks' one-on-one king, a title he will wear with pride and continue to defend with every ounce of his being.Inter Milan, on the other hand, is facing a dilemma regarding the future of Esposito. The Nerazzurri are keen on keeping hold of the talented forward, but Napoli's interest and the relatively low buyout clause in his contract could tempt them to cash in on the player this summer. With Inter Milan facing financial constraints and the need to balance the books, selling Esposito for 5 million euros could be an attractive option for the club.
At the core of China's stance on Sino-Korean relations is a deep respect for South Korea's internal affairs. The Chinese Ministry of Foreign Affairs has consistently emphasized the importance of non-interference in the domestic affairs of sovereign nations, including South Korea. This principle of respect for sovereignty and territorial integrity forms the foundation of China's approach to diplomatic relations with other countries, including South Korea.The A-share market, which refers to stocks traded on mainland Chinese exchanges such as the Shanghai and Shenzhen stock exchanges, has seen a remarkable rally in recent trading sessions. With over 5,000 individual stocks witnessing price increases, the market sentiment has been overwhelmingly bullish. This surge in stock prices has been attributed to a variety of factors, including strong corporate earnings, positive economic data, and robust investor sentiment.
Upon receiving the email, the supervisor immediately alerted the HR department about the breach of the company's compensation confidentiality policy. After conducting an investigation, it was determined that the employee had indeed violated the established guidelines by sharing sensitive salary information with their superior without authorization. As a result, the employee was terminated from their position, causing shock and outrage among their colleagues and sparking a heated debate within the company.3 ASX growth stocks I want in my Christmas stocking this year
In the fast-paced and competitive real estate market of Jiangsu Province, the performance of both real estate enterprises and local state-owned enterprises plays a vital role in reflecting the economic development and growth of the region. From January to November 2024, the sales achievements of these enterprises have been closely monitored and evaluated. Let's delve into the ranking of the top-performing companies during this period.
Friendly reminder |
The authenticity of this information has not been verified by this website and is for your reference only. Please do not reprint without permission. If authorized by this website, it should be used within the scope of authorization and marked with "Source: this website". |
Special attention |
Some articles on this website are reprinted from other media. The purpose of reprinting is to convey more industry information, which does not mean that this website agrees with their views and is responsible for their authenticity. Those who make comments on this website forum are responsible for their own content. This website has the right to reprint or quote on the website. The comments on the forum do not represent the views of this website. If you need to use the information provided by this website, please contact the original author. The copyright belongs to the original author. If you need to contact this website regarding copyright, please do so within 15 days. |